Barclays Sticks to Its Buy Rating for Coca Cola Femsa SAB De CV (KOF)
Analyst Rating: Benjamin Theurer from Barclays has maintained a Buy rating on Coca Cola Femsa SAB De CV (KOF) with a price target of $99.00, while the current share price is $88.39.
Market Consensus: Coca Cola Femsa SAB De CV holds an analyst consensus of Strong Buy, with a price target consensus of $96.87, and its shares have fluctuated between a one-year high of $102.28 and a low of $72.68.
Trade with 70% Backtested Accuracy
Analyst Views on KOF
About KOF
About the author
Coca-Cola Femsa Analyst Changes Stance; Discover Tuesday's Two Major Downgrades
Analyst Downgrades: Barclays analyst Benjamin Theurer downgraded Coca-Cola Femsa SAB de CV from Overweight to Equal-Weight, maintaining a price target of $98, while shares closed at $87.60.
10x Genomics Rating Change: Morgan Stanley analyst Tejas Savant downgraded 10x Genomics, Inc. from Overweight to Equal-Weight, raising the price target from $17 to $20, with shares closing at $18.08.
Market Overview: The article provides a snapshot of various stocks, including Coca-Cola Femsa and 10x Genomics, along with their recent performance and analyst ratings.
Investment Advice Disclaimer: The content is sourced from Benzinga, which does not provide investment advice and emphasizes the importance of consulting analysts for stock evaluations.
UBS Reiterates Buy Rating on Coca-Cola Femsa SAB de, Adjusts Price Target to $109
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Earnings Report Ahead of Market Opening for October 24, 2025: PG, SNY, HCA, GD, ITW, BAH, GNTX, FLG, FHB, KOF, STEL, VRTS
Earnings Reports Overview: Several companies, including Procter & Gamble, Sanofi, and HCA Healthcare, are set to report their earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
Procter & Gamble Performance: PG's expected earnings per share (EPS) is $1.90, reflecting a 1.55% decrease from last year, while it has met or beaten analyst expectations in three of the last four quarters.
HCA Healthcare Growth: HCA is projected to report an EPS of $5.65, indicating an 11.88% increase year-over-year, having consistently beaten expectations in the past year.
Mixed Results Across Industries: Companies like Booz Allen Hamilton and Gentex are expected to see decreases in EPS, while others like Illinois Tool Works and First Hawaiian are forecasted to show growth, highlighting diverse performance across sectors.
Analysts Predict 11% Growth for PID in the Future
ETF Analysis: The Invesco International Dividend Achievers ETF (PID) has an implied analyst target price of $23.98 per unit, indicating an 11.44% upside from its recent trading price of $21.52.
Notable Holdings: Key underlying holdings with significant upside potential include PLDT Inc (64.81% upside), Coca-Cola FEMSA (26.93% upside), and Sanofi (26.61% upside), collectively representing 9.29% of PID.
Coca-Cola FEMSA's (NYSE:KOF) Capital Returns Continue to Show Strong Growth
Coca-Cola FEMSA's Financial Metrics: The company shows promising trends with a return on capital employed (ROCE) of 16%, which is close to the beverage industry's average of 18%. Over the last five years, ROCE has grown by 36% while capital employed has remained stable.
Investment Potential and Risks: Coca-Cola FEMSA has delivered a remarkable 160% total return over five years, indicating strong investor confidence. However, there is one warning sign to be aware of, suggesting potential risks associated with the investment.
Projected Target Price for PID Analyst: $23
ETF Target Price Analysis: The Invesco International Dividend Achievers ETF (PID) has an implied analyst target price of $23.36 per unit, indicating a potential upside of 10.47% from its current trading price of $21.15.
Notable Holdings with Upside: Key underlying holdings in PID, such as PLDT Inc (PHI), Sanofi (SNY), and Coca-Cola FEMSA (KOF), show significant upside potential, with target prices suggesting increases of 59.08%, 26.94%, and 25.30% respectively from their recent trading prices.
Coca-Cola Femsa Analyst Changes Stance; Discover Tuesday's Two Major Downgrades
Analyst Downgrades: Barclays analyst Benjamin Theurer downgraded Coca-Cola Femsa SAB de CV from Overweight to Equal-Weight, maintaining a price target of $98, while shares closed at $87.60.
10x Genomics Rating Change: Morgan Stanley analyst Tejas Savant downgraded 10x Genomics, Inc. from Overweight to Equal-Weight, raising the price target from $17 to $20, with shares closing at $18.08.
Market Overview: The article provides a snapshot of various stocks, including Coca-Cola Femsa and 10x Genomics, along with their recent performance and analyst ratings.
Investment Advice Disclaimer: The content is sourced from Benzinga, which does not provide investment advice and emphasizes the importance of consulting analysts for stock evaluations.
UBS Reiterates Buy Rating on Coca-Cola Femsa SAB de, Adjusts Price Target to $109
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Earnings Report Ahead of Market Opening for October 24, 2025: PG, SNY, HCA, GD, ITW, BAH, GNTX, FLG, FHB, KOF, STEL, VRTS
Earnings Reports Overview: Several companies, including Procter & Gamble, Sanofi, and HCA Healthcare, are set to report their earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
Procter & Gamble Performance: PG's expected earnings per share (EPS) is $1.90, reflecting a 1.55% decrease from last year, while it has met or beaten analyst expectations in three of the last four quarters.
HCA Healthcare Growth: HCA is projected to report an EPS of $5.65, indicating an 11.88% increase year-over-year, having consistently beaten expectations in the past year.
Mixed Results Across Industries: Companies like Booz Allen Hamilton and Gentex are expected to see decreases in EPS, while others like Illinois Tool Works and First Hawaiian are forecasted to show growth, highlighting diverse performance across sectors.
Analysts Predict 11% Growth for PID in the Future
ETF Analysis: The Invesco International Dividend Achievers ETF (PID) has an implied analyst target price of $23.98 per unit, indicating an 11.44% upside from its recent trading price of $21.52.
Notable Holdings: Key underlying holdings with significant upside potential include PLDT Inc (64.81% upside), Coca-Cola FEMSA (26.93% upside), and Sanofi (26.61% upside), collectively representing 9.29% of PID.
Coca-Cola FEMSA's (NYSE:KOF) Capital Returns Continue to Show Strong Growth
Coca-Cola FEMSA's Financial Metrics: The company shows promising trends with a return on capital employed (ROCE) of 16%, which is close to the beverage industry's average of 18%. Over the last five years, ROCE has grown by 36% while capital employed has remained stable.
Investment Potential and Risks: Coca-Cola FEMSA has delivered a remarkable 160% total return over five years, indicating strong investor confidence. However, there is one warning sign to be aware of, suggesting potential risks associated with the investment.
Projected Target Price for PID Analyst: $23
ETF Target Price Analysis: The Invesco International Dividend Achievers ETF (PID) has an implied analyst target price of $23.36 per unit, indicating a potential upside of 10.47% from its current trading price of $21.15.
Notable Holdings with Upside: Key underlying holdings in PID, such as PLDT Inc (PHI), Sanofi (SNY), and Coca-Cola FEMSA (KOF), show significant upside potential, with target prices suggesting increases of 59.08%, 26.94%, and 25.30% respectively from their recent trading prices.
